Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Phenergan

Phenergan
In stock
10mg · 25mg
from A$44.52
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$59.22A$44.52
A$1.48 per tablet

In brief

  • In many countries (including Australia) Phenergan is normally a prescription medicine, but it is often possible to buy phenergan from some pharmacies without a receipt or formal prescription; availability varies by pharmacy and local regulations so confirm with the pharmacist before purchase.
  • Phenergan (promethazine hydrochloride) is used for allergic conditions, nausea and vomiting, motion sickness and as a sedative/pre‑medication; it works mainly as an H1 antihistamine with anticholinergic and sedative effects and antiemetic action via central H1/muscarinic receptor blockade.
  • Usual adult doses: 10–25 mg at night or 10 mg two to three times daily for allergic symptoms; 25 mg (sometimes 25–50 mg) for nausea/motion sickness or pre‑op sedation (can repeat every 4–6 hours as directed). Children: lower weight‑based doses (e.g. 5–15 mg or 12.5–25 mg for motion sickness) and not recommended under 2 years.
  • Forms of administration: oral tablets (10 mg, 25 mg), oral elixir/syrup (1 mg/mL), rectal suppositories (where available); in hospital settings parenteral routes (IM/IV) may be used under clinician supervision.
  • Onset time: oral doses usually begin to work within about 15–60 minutes (IM is faster, often within 10–30 minutes).
  • Duration of action: effects commonly last around 4–12 hours; sedation and anticholinergic effects can persist longer (and be prolonged in the elderly or in liver impairment).
  • Alcohol warning: do not drink alcohol while taking phenergan — alcohol markedly increases drowsiness and CNS depression and can be dangerous; avoid driving or operating heavy machinery.
  • The most common side effec is sedation/drowsiness.
  • Would you like to try phenergan without a prescription?

Basic Phenergan Information

  • INN (International Nonproprietary Name): Promethazine hydrochloride.
  • Brand Names Available In Australia: Phenergan — Tablets 10mg and 25mg; Elixir 1mg/mL (100mL bottle).
  • ATC Code: R06AD02.
  • Forms & Dosages: Tablets 10mg and 25mg in blister packs (25/50); Elixir 1mg/mL in 100mL bottle; suppository forms (12.5mg, 25mg, 50mg) are less commonly available.
  • Manufacturers In Australia: sanofi-aventis australia pty ltd.
  • Registration Status In Australia: TGA Registered — AUST R 80159 and 80160 for tablets; AUST R 61576 for elixir.
  • OTC / Rx Classification: Prescription medication (Rx) in Australia.

Critical Warnings & Restrictions

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

Promethazine (INN: promethazine hydrochloride) must not be used in children under 2 years because of the risk of fatal respiratory depression.

Elderly people need dose reduction and close monitoring for sedation, confusion and hypotension.

Review use carefully in severe hepatic or renal impairment, epilepsy, narrow‑angle glaucoma, prostatic hypertrophy and significant cardiovascular disease.

TGA registration and product labelling obligations apply to Phenergan tablets (10mg/25mg) and elixir (1mg/mL), with registration numbers AUST R 80159, 80160 and 61576.

Pregnancy and breastfeeding require prescriber or pharmacist review and should be used only if benefits outweigh risks and under specialist advice.

  • Contraindications: hypersensitivity to promethazine or phenothiazine derivatives.
  • Contraindications: children under 2 years of age.
  • Contraindications: comatose states, severe CNS depression or severe respiratory suppression.
  • Relative Contraindications: severe hepatic or renal impairment; history of seizures; narrow‑angle glaucoma; prostatic hypertrophy; urinary retention; significant cardiovascular disease.
  1. Seek immediate medical review for any breathing difficulty, extreme sleepiness that is not improving, or collapse after taking promethazine.
  2. Go to emergency care for severe agitation, very rapid heartbeat, or signs of an allergic reaction such as swelling of face or throat.
  3. Contact your prescriber urgently if a child younger than 2 years has been given promethazine.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Promethazine commonly causes sedation, impaired alertness and slowed reaction times.

Australian workplace health and safety (WHS) expectations require disclosure of sedative medication for safety‑critical roles such as drivers, machine operators and some healthcare workers.

Workers should follow their employer’s fit‑for‑duty policies and may need dose timing changes or temporary role adjustments.

When clinically appropriate, consider night‑time dosing for symptom control to reduce daytime impairment.

  • Checklist For Fit‑For‑Duty Considerations: disclose medication to employer; request a work‑safety assessment; avoid safety‑critical tasks until effects are known; get written advice from prescriber or pharmacist if required.
  • Employer Communication Template: state your name, role, medication name (promethazine), dosing times, and that you have been advised that sedation or impaired alertness is a possible effect.
  • Employer Communication Template: ask for temporary reassignment or adjustments until you and the clinician confirm you are fit for duties.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Can I drive after taking Phenergan?

A: No — do not drive or operate heavy machinery until you know how promethazine affects you.

A: It commonly causes drowsiness and slowed reaction times and Australian road safety laws treat driving while impaired as illegal.

A: If sedation occurs, arrange alternative transport and inform your prescriber or pharmacist about your driving or work needs so dosing can be reviewed.

Usage Basics

INN, Brand Names Available In Australia

The International Nonproprietary Name is promethazine hydrochloride.

In Australia the primary brand is Phenergan with tablet strengths of 10mg and 25mg and an elixir at 1mg/mL in a 100mL bottle.

Other international brands include Avomine, Lergigan and similar promethazine preparations when referenced in comparative material.

The Australian manufacturer listed for Phenergan is sanofi‑aventis australia pty ltd.

  • INN: Promethazine hydrochloride.
  • ATC: R06AD02.
  • Brand: Phenergan (Australia).
  • Manufacturer: sanofi‑aventis australia pty ltd.
  • Available Forms: Tablets 10mg, 25mg.
  • Available Forms: Elixir 1mg/mL (100mL).
  • Available Forms: Suppositories are less commonly available and may not be sold in all countries.

Legal Classification (TGA‑Approved, PBS‑Listed)

Phenergan is a prescription medicine in Australia and is registered with the TGA.

Tablets carry registration numbers AUST R 80159 and 80160 and the elixir is AUST R 61576.

PBS listing varies by indication and formulation and many common uses such as motion sickness are private prescriptions rather than PBS subsidised items.

Patients should ask their prescriber or pharmacist about PBS eligibility and any concession entitlements that may apply.

  • TGA Registration Numbers: Tablets — AUST R 80159, AUST R 80160; Elixir — AUST R 61576.
  • PBS Note: Subsidy depends on indication and formulation; check the PBS Schedule for current status.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Typical adult dosing from product information depends on indication.

For allergic conditions adults usually take 10–25mg at night or 10mg two to three times daily.

For motion sickness adults commonly take 25mg the night before travel or 1–2 hours before exposure; children may receive 12.5–25mg as a single pre‑travel dose depending on age and weight.

For nausea and vomiting adults may use 25–50mg and repeat every 4–6 hours if clinically indicated under prescriber advice.

Tablets are available as 10mg and 25mg strengths and the elixir is 1mg/mL in a 100mL bottle.

Indication Adults Children Max Frequency
Allergic Conditions 10–25mg at night or 10mg 2–3x/day 5–15mg at night or divided doses (6+ years) Every 8–24 hours as needed
Pre‑operative Sedation 25–50mg single pre‑op dose Dose per weight under MD guidance Single use
Motion Sickness 25mg night before or 1–2 hours prior 12.5–25mg single dose before travel Single or repeat per clinician advice
Nausea/Vomiting 25–50mg, can repeat every 4–6 hours if required As directed by specialist Every 4–6 hours under supervision

Weight‑based paediatric dosing and hospital dosing should be calculated by clinicians and are used in inpatient settings.

Adjustments For Comorbidities

Reduce dose in elderly patients and those with hepatic or renal impairment because of increased sensitivity and prolonged effects.

Avoid use in infants under 2 years of age.

In people with seizure disorders review risk and benefit as promethazine may lower seizure threshold.

Always document hepatic and renal status and concurrent CNS depressant use in the clinical record.

  • Checklist For Prescriber Dose Review: age, hepatic function, renal function, seizure history, concurrent opioids or benzodiazepines.

Q&A — “What If I Miss A Dose?”

Q: Missed a dose of Phenergan — what to do?

A: Take the missed dose as soon as you remember unless the next dose is near.

A: Do not double up doses to make up for a missed dose.

A: For single‑use motion‑sickness doses skip a missed pre‑travel dose and use the next planned dose only if needed and safe.

A: Contact a pharmacist or prescriber if unsure.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol is a major interaction and potentiates sedation and respiratory depression with promethazine.

Caffeine may temporarily offset drowsiness but is not a safe or recommended strategy to compensate for impairment.

Consider common Australian drinking patterns such as social drinking at events, long‑distance driving after festivals, and farm work when counselling patients.

  • High‑Risk Beverages: alcoholic drinks of any strength; spirits, wine and beer all increase sedative risk.
  • High‑Risk Beverages: energy drinks and high caffeine drinks are not reliable to reverse sedation and can cause other adverse effects.
  • Rural/Outdoor Workers: avoid alcohol and time doses to reduce overlap with machinery operation or long drive periods.

Common Drug Conflicts

Promethazine interacts with multiple drug classes and can cause clinically important additive effects.

Combine with other CNS depressants such as opioids or benzodiazepines increases sedation and respiratory depression risk.

MAO inhibitors augment anticholinergic and hypotensive effects and should be avoided or used only after specialist advice.

Concomitant anticholinergics increase dry mouth, urinary retention and constipation.

Drug Class Interaction Clinical Action
Opioids Increased sedation and respiratory depression Avoid combination where possible; if necessary, use lowest doses and close monitoring
Benzodiazepines/Sedative Hypnotics Enhanced CNS depression Reduce doses and advise against driving; monitor respiratory status
MAO Inhibitors Increased anticholinergic and hypotensive effects Avoid use or consult specialist before co‑prescribing
Tricyclic Antidepressants/Antimuscarinics Increased anticholinergic burden (urinary retention, constipation) Monitor anticholinergic side effects; consider alternatives
CYP Inhibitors/Inducers May alter promethazine levels Review interacting drugs and consider dose adjustment

User Reports & Trends

What do patients in Australia say about Phenergan?

Online forums and ProductReview entries commonly report effective relief for motion sickness and useful short‑term sleepiness.

Frequent comments describe daytime drowsiness and residual grogginess the next morning.

There are occasional reports of paradoxical agitation or excitation in some children.

Supply and price sensitivity are common themes, with users often comparing pharmacy chains and seeking telehealth scripts for convenience.

Anecdotal feedback is subjective and should be combined with clinical guidance for decision making.

  • Patient‑Reported Benefits: effective for motion sickness; useful for short‑term sedation and allergy relief.
  • Patient‑Reported Adverse Effects: daytime drowsiness; dry mouth; occasional agitation in children.
  • Access Themes: price comparison between Chemist Warehouse, Priceline and independents; telehealth scripts used by many buyers.
Sentiment Typical Comments
Positive Works well for travel sickness and short‑term sleep aid.
Neutral Effective but causes drowsiness; acceptable for night use.
Negative Excessive grogginess or paradoxical effects in children.

Access & Purchase Options

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Phenergan tablets and elixir are commonly stocked across community pharmacies in Australia.

Prices vary by chain, pack size and special offers and may be listed online for private purchase.

Because many indications are not PBS subsidised, private prescription purchases are common.

Pharmacy Likely Stock Forms Typical Price Range
Chemist Warehouse Phenergan tablets 10mg/25mg; Elixir 1mg/mL $8–$25 (estimate, private purchase)
Priceline Phenergan tablets; Elixir where available $10–$30 (estimate, private purchase)
TerryWhite Chemmart Phenergan tablets; Elixir on request $12–$28 (estimate, private purchase)

Prices are indicative and should be verified in store or online at the time of purchase.

Online Pharmacies And Telehealth E‑Prescriptions

Australian telehealth services can issue e‑prescriptions for Phenergan where clinically appropriate following an assessment.

Patients should verify identity and provide a complete medication history before an e‑script is issued.

Use registered online pharmacies and ensure the supplier is TGA‑approved.

Rural patients can use delivery services but should check heat exposure risks for elixir during transit.

  • Checklist For Safe Online Purchasing: ensure prescription is required and present; confirm the pharmacy is Australian registered; confirm pharmacist contact details; check delivery times and packaging standards.

In our online pharmacy, phenergan is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Mechanism & Pharmacology

Simplified Explanation

Promethazine is a phenothiazine‑derived antihistamine and works primarily as an H1 receptor antagonist.

The drug has strong sedative and anticholinergic properties which explain drowsiness, dry mouth and blurred vision.

Its antiemetic and sedative effects arise from central H1 antagonism and antimuscarinic activity at the vomiting centre.

  • H1 Antagonist: blocks histamine H1 receptors to reduce allergic symptoms.
  • Anticholinergic: reduces parasympathetic activity causing dry mouth and urinary retention.
  • Antiemetic: central action on vomiting pathways reduces nausea and motion sickness.

Clinical Terms

Promethazine has significant CNS penetration, and half‑life can be prolonged in hepatic impairment.

Enhanced effects occur with other CNS depressants such as opioids or benzodiazepines.

  • Clinical Implication: monitor for excessive sedation and respiratory depression in vulnerable patients.
  • Clinical Implication: reduce dose in hepatic or renal impairment and in the elderly.
  • Monitoring Markers: level of consciousness, respiratory rate, blood pressure and urinary output.

Indications & Off‑Label Uses

Approved Indications By TGA

TGA‑labelled uses for Phenergan include symptomatic allergic conditions, motion sickness, pre‑operative sedation and short‑term control of nausea and vomiting in adults.

Dosage forms on the label are tablets (10mg/25mg) and elixir (1mg/mL).

Indication Common Adult Dose Usual Duration
Allergic Conditions 10–25mg at night or 10mg 2–3x/day Short course during symptomatic periods
Motion Sickness 25mg night before or 1–2 hrs prior Single or short‑term use
Pre‑operative Sedation 25–50mg single dose Single pre‑op dose
Nausea/Vomiting 25–50mg, repeat every 4–6 hours if required Short‑term under supervision

Off‑Label Uses In Australian Clinical Practice

Promethazine is sometimes used off‑label for short‑term insomnia or palliative nausea when other agents are unsuitable.

Use in palliative care is under specialist supervision and requires careful documentation.

  • Checklist For Off‑Label Prescribing: document indication, expected benefits, risks discussed, and patient or carer consent.

Key Clinical Findings

Recent Australian and international evidence through 2022–2026 confirms efficacy for motion sickness and short‑term sedation.

Regulatory updates emphasise increased risk in young children and the elderly.

Safety literature strongly highlights the risk of respiratory depression in infants and additive respiratory depression when combined with opioids.

  • Key Study Outcomes: effective antiemetic effect for motion sickness and acceptable short‑term sedation in adults.
  • Regulatory Alerts: contraindication in children under 2 years; warnings about co‑administration with opioids and other CNS depressants.
  • Primary References: product registration and TGA product information.

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Medicine Sedation Level PBS Status Common Uses Notes
Chlorphenamine Moderate Varies by indication Allergic rhinitis, urticaria Good alternative for allergy; sedating.
Diphenhydramine High Less commonly PBS‑listed Allergy, short‑term insomnia Highly sedating; similar anticholinergic burden.
Cetirizine Low Commonly PBS‑listed for some indications Allergic rhinitis, urticaria Less sedating; suitable for daytime use.
Loratadine Low Commonly PBS‑listed for some indications Allergic rhinitis, urticaria Non‑sedating; good for drivers and shift workers.

Pros And Cons Checklist

  • Phenergan Pros: effective antiemetic and anti‑allergic; widely available in tablets and elixir.
  • Phenergan Cons: high sedation, significant anticholinergic burden, contraindicated under 2 years old.
  • Non‑Sedating Alternatives Pros: better for daytime function and driving.
  • Non‑Sedating Alternatives Cons: may be less effective for severe vomiting or pre‑op sedation.
  • Decision Checklist For Clinicians: match patient activity needs, age, comorbidities and concomitant meds before selecting therapy.

Common Questions (Pharmacy Consultations)

Which interactions worry patients most?

Alcohol and opioids are the most important interactions to flag due to respiratory depression risk.

Patients commonly ask about driving and workplace safety, child dosing, pregnancy and breastfeeding, and proper storage.

Provide concise counselling: check allergy history, current medications, pregnancy status, and recommend the lowest effective dose for the shortest period.

Advise patients to avoid alcohol and other CNS depressants and to report excessive sedation.

  • Micro‑FAQ: Can I drink alcohol? — No, avoid alcohol while taking promethazine.
  • Micro‑FAQ: Is it safe in pregnancy? — Review with a prescriber; use only if benefits outweigh risks.
  • Micro‑FAQ: What about child dosing? — Not for children under 2 years; older children need specialist dosing.
  • Consultation Checklist For Pharmacists: confirm indication, dose, review interactions, provide written dosing instructions, and document counselling.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Pharmacy/Source Format Stocked Price Range (Estimate) PBS Subsidy Prescription Required
Chemist Warehouse Tablets 10mg/25mg; Elixir $8–$25 Limited; depends on indication Yes
Priceline Tablets; Elixir $10–$30 Limited Yes
Independent Pharmacies Tablets; may stock Elixir $12–$35 Limited Yes
Online Pharmacies Tablets and Elixir via prescription $10–$35 plus delivery Limited Yes or telehealth e‑script

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Confirm the product is TGA‑registered and match AUST R numbers when in doubt.
  • Verify a valid prescription or telehealth e‑script before purchase.
  • Ask about delivery times and insulated packaging for elixir in hot weather.
  • Rural patients should allow extra delivery time and request tamper‑evident packaging.

Registration & Regulation

TGA Approval

Phenergan tablets and elixir are TGA‑registered with numbers AUST R 80159 and 80160 for tablets and AUST R 61576 for elixir.

Prescribing should follow product information and TGA guidance including contraindications in children under 2 and cautions about co‑administration with opioids or other CNS depressants.

  • Regulatory Obligations For Prescribers: follow product information, document indication, and counsel on risks for vulnerable patients.
  • Regulatory Obligations For Pharmacists: check prescriptions, counsel on sedation risk, and report adverse events as required.
  • Report Adverse Events Via TGA: document and submit reports when serious side effects occur.

PBS Subsidy Details

PBS listing is indication and formulation dependent and many common uses are not subsidised.

Encourage clinicians and patients to check the current PBS Schedule and Medicare entitlements for up‑to‑date subsidy information.

  • Checklist For Checking PBS Eligibility: confirm indication, confirm formulation, check concession status, and consult PBS online if unsure.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store Phenergan below 30°C, out of direct sunlight and away from moisture.

Keep the elixir tightly closed and out of reach of children.

Label bottles with dosing instructions and expiry dates.

During Australian summer or for rural mail delivery, use insulated packaging if ambient temperatures may exceed recommended limits.

  • Home Storage Checklist: store in a cool, dry cupboard; keep original packaging; keep out of reach of children; do not refrigerate unless instructed.
  • Travel Packing Tips: carry in hand luggage for air travel; protect elixir from extreme heat.

Cold‑Chain Handling For Pharmacies

Phenergan is not a refrigerated product but pharmacies must store and transport it per manufacturer guidance.

Maintain batch records and expiry checks for stock control.

  • Pharmacy SOP Items: check incoming stock temperature, store below 30°C, document dispatch and advise couriers of heat exposure limits.

Guidelines For Proper Use

Australian Pharmacist Counselling Style

Start consultations by confirming the patient’s identity and the indication for treatment.

Explain expected effects such as sedation and anticholinergic symptoms plainly.

Provide clear dosing schedules and advise when to seek medical help for breathing difficulties, extreme sedation or agitation.

Discuss interactions with alcohol and opioids and document counselling in the patient medication record.

  • Model Counselling Script: patient name, reason for use, dose and timing, expected effects, what to avoid, and when to seek help.
  • Patient Handout Template: written dose instructions, side effect checklist, emergency contact details, and return instructions for unused medicine.

Patient Advice From PBS And National Health Authorities

Use the lowest effective dose for the shortest possible duration in line with TGA and PBS guidance.

Avoid use in infants under 2 years and seek prescriber review for pregnancy, breastfeeding and chronic use.

Report adverse events through the TGA Adverse Event reporting system.

  • Resources: check TGA product information and PBS pages for the latest guidance and regulatory updates.
  • Patient Action Plan For Adverse Effects: stop medication if severe reaction occurs, seek immediate medical care, and report the event to the prescriber and TGA.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 14-21 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Gold Coast Queensland 9-14 days
Sunshine Coast Queensland 9-14 days
Geelong Victoria 9-14 days
Cairns Queensland 14-21 days

Closing Notes For Clinicians And Patients

Phenergan (promethazine hydrochloride) is a useful medicine for motion sickness, short‑term sedation and allergic symptoms when used appropriately.

Careful patient selection, dose adjustment in the elderly and avoidance in children under 2 years are essential safety measures.

Always review the full medication list for interactions, particularly with opioids and other CNS depressants.

When prescribing off‑label, document rationale and obtain informed consent.

For additional regulatory details consult TGA product information and related guidance.

For international regulatory queries the ANMDMR portal provides national data for Romania and European markets.

ANMDMR portal

Related products